Granted Patent
B2
US 12,616,752 · App. 19/229,702 · Granted May 5, 2026
Pharmaceutical compositions comprising meloxicam
Assignee:
Axsome Therapeutics, Inc.
A61K47/02A61K9/0053A61K9/2009A61K31/4196A61K31/4439A61K31/5415A61K45/06A61K47/40A61K47/6951A61P25/06C08B37/0012C08B37/0015
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T max of meloxicam of 3 hours or less.
Claims (19)
1 . A method of rapidly delivering meloxicam to the blood of a human being comprising orally administering a solid dosage form to a human being in need of treatment of pain, wherein the dosage form comprises meloxicam or a pharmaceutically acceptable salt thereof and 1 mg to 1000 mg of a bicarbonate, and wherein the solid dosage form provides a T max of meloxicam in the human being that is less than 4 hours.
2 . The method of claim 1 , wherein the T max of meloxicam in the human being is less than 1 hour.
3 . The method of claim 1 , wherein the T max of meloxicam in the human being is between 1-4 hours.
4 . The method of claim 1 , wherein the T max of meloxicam in the human being is between 10 minutes-180 minutes.
5 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that is observed at less than 15 minutes.
6 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that is observed at less than 20 minutes.
7 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that is observed at less than 30 minutes.
8 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that is observed at less than one hour.
9 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that lasts at least four hours.
10 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that lasts at least eight hours.
11 . The method of claim 1 , wherein orally administering the solid dosage form achieves a reduction in pain that lasts at least twenty-four hours.
12 . The method of claim 1 , wherein the solid dosage form comprises 1-50 mg meloxicam.
13 . The method of claim 1 , wherein the solid dosage form comprises 1-15 mg meloxicam.
14 . The method of claim 1 , wherein the pain is an acute pain.
15 . The method of claim 1 , wherein the pain is a pain affecting a muscle.
16 . The method of claim 1 , wherein the pain is a pain affecting a bone.
17 . The method of claim 1 , wherein the pain is a pain affecting a ligament.
18 . The method of claim 1 , wherein the pain is a pain affecting a tendon.
19 . The method of claim 1 , wherein the solid dosage form comprises a cyclodextrin or a pharmaceutically acceptable salt thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 21, 2025
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 072360/0140 →
Continuity (14)
Provisional Application
62536466
· Jul 25, 2017
Provisional Application
62526884
· Jun 29, 2017
References Cited (363)
US 4233299A
· Trummlitz et al.
· 1980
[cited by applicant]
US 5872145A
· Plachetka
· 1999
[cited by applicant]
US 6060499A
· Plachetka
· 2000
[cited by applicant]
US 6077539A
· Plachetka et al.
· 2000
[cited by applicant]
US 6284269B1
· Struengmann et al.
· 2001
[cited by applicant]
US 6384034B2
· Simitchieva et al.
· 2002
[cited by applicant]
US 6479551B1
· Plachetka et al.
· 2002
[cited by applicant]
US 6495535B1
· Plachetka et al.
· 2002
[cited by applicant]
US 6586458B1
· Plachetka
· 2003
[cited by applicant]
US 6926907B2
· Plachetka
· 2005
[cited by applicant]
US 7030162B2
· Plachetka et al.
· 2006
[cited by applicant]
US 7060694B2
· Plachetka et al.
· 2006
[cited by applicant]
US 7332183B2
· Plachetka et al.
· 2008
[cited by applicant]
US 8022095B2
· Plachetka
· 2011
[cited by applicant]
US 8206741B2
· Plachetka
· 2012
[cited by applicant]
US 8512727B2
· Cooper
· 2013
[cited by applicant]
US 8557285B2
· Plachetka
· 2013
[cited by applicant]
US 8835407B2
· Mosher et al.
· 2014
[cited by applicant]
US 8852636B2
· Plachetka
· 2014
[cited by applicant]
US 8858996B2
· Plachetka
· 2014
[cited by applicant]
US 8865190B2
· Plachetka
· 2014
[cited by applicant]
US 8945621B2
· Ault et al.
· 2015
[cited by applicant]
US 9161920B2
· Plachetka
· 2015
[cited by applicant]
US 9198888B2
· Plachetka
· 2015
[cited by applicant]
US 9220698B2
· Ault et al.
· 2015
[cited by applicant]
US 9265732B2
· Plachetka et al.
· 2016
[cited by applicant]
US 9345695B2
· Plachetka
· 2016
[cited by applicant]
US 9364439B2
· Plachetka
· 2016
[cited by applicant]
US 9393208B2
· Ault et al.
· 2016
[cited by applicant]
US 9539214B2
· Plachetka
· 2017
[cited by applicant]
US 9707181B2
· Plachetka
· 2017
[cited by applicant]
US 9801824B2
· Ault et al.
· 2017
[cited by applicant]
US 9801827B2
· Plachetka et al.
· 2017
[cited by applicant]
US 9821075B2
· Tabuteau
· 2017
[cited by applicant]
US 20020016348A1
· Simitchieva et al.
· 2002
[cited by applicant]
US 20020035107A1
· Henke et al.
· 2002
[cited by applicant]
US 20030008003A1
· Jamali
· 2003
[cited by applicant]
US 20040214861A1
· Seibert
· 2004
[cited by applicant]
US 20040229038A1
· Cooper et al.
· 2004
[cited by applicant]
US 20050249806A1
· Proehl et al.
· 2005
[cited by applicant]
US 20070154542A1
· Tananbaum et al.
· 2007
[cited by applicant]
US 20070281927A1
· Tyavanagimatt et al.
· 2007
[cited by applicant]
US 20090068262A1
· Zalit et al.
· 2009
[cited by applicant]
US 20090203680A1
· Hanna et al.
· 2009
[cited by applicant]
US 20090311335A1
· Jenkins et al.
· 2009
[cited by applicant]
US 20100226943A1
· Brennan et al.
· 2010
[cited by applicant]
US 20130266658A1
· Weiß et al.
· 2013
[cited by applicant]
US 20140248353A1
· Ryoo et al.
· 2014
[cited by applicant]
US 20160228576A1
· Tabuteau
· 2016
[cited by applicant]
US 20180050106A1
· Tabuteau
· 2018
[cited by applicant]
US 20180127490A1
· Bigal et al.
· 2018
[cited by applicant]
US 20180207274A1
· Tabuteau
· 2018
[cited by applicant]
US 20180214380A1
· Tabuteau
· 2018
[cited by applicant]
US 20180256593A1
· Tabuteau
· 2018
[cited by applicant]
US 20180264114A1
· Tabuteau
· 2018
[cited by applicant]
US 20180264115A1
· Tabuteau
· 2018
[cited by applicant]
US 20180271981A1
· Tabuteau
· 2018
[cited by applicant]
US 20180280306A1
· Tabuteau
· 2018
[cited by applicant]
US 20180280308A1
· Tabuteau
· 2018
[cited by applicant]
US 20180280512A1
· Tabuteau
· 2018
[cited by applicant]
US 20180289806A1
· Tabuteau
· 2018
[cited by applicant]
US 20180289807A1
· Tabuteau
· 2018
[cited by applicant]
US 20180289808A1
· Tabuteau
· 2018
[cited by applicant]
US 20190000975A1
· Tabuteau
· 2019
[cited by applicant]
US 20190070192A1
· Tabuteau
· 2019
[cited by applicant]
US 20190142942A1
· Tabuteau
· 2019
[cited by applicant]
US 20190142943A1
· Tabuteau
· 2019
[cited by applicant]
US 20190224320A1
· Tabuteau
· 2019
[cited by applicant]
US 20190224321A1
· Tabuteau
· 2019
[cited by applicant]
US 20190231792A1
· Tabuteau
· 2019
[cited by applicant]
US 20190255177A1
· Tabuteau
· 2019
[cited by applicant]
US 20190307884A1
· Tabuteau
· 2019
[cited by applicant]
US 20190314504A1
· Tabuteau
· 2019
[cited by applicant]
US 20190336510A1
· Tabuteau
· 2019
[cited by applicant]
US 20200000819A1
· Tabuteau
· 2020
[cited by applicant]
US 20200000820A1
· Tabuteau
· 2020
[cited by applicant]
US 20200000919A1
· Tabuteau
· 2020
[cited by applicant]
US 20200000920A1
· Tabuteau
· 2020
[cited by applicant]
US 20200000921A1
· Tabuteau
· 2020
[cited by applicant]
US 20200000922A1
· Tabuteau
· 2020
[cited by applicant]
US 20200009250A1
· Tabuteau
· 2020
[cited by applicant]
US 20200030338A1
· Tabuteau
· 2020
[cited by applicant]
US 20200038408A1
· Tabuteau
· 2020
[cited by applicant]
US 20200085951A1
· Tabuteau
· 2020
[cited by applicant]
US 20200085952A1
· Tabuteau
· 2020
[cited by applicant]
US 20200085953A1
· Tabuteau
· 2020
[cited by applicant]
US 20200085954A1
· Tabuteau
· 2020
[cited by applicant]
US 20200085955A1
· Tabuteau
· 2020
[cited by applicant]
US 20200155565A1
· Tabuteau
· 2020
[cited by applicant]
US 20200179396A1
· Tabuteau
· 2020
[cited by applicant]
US 20200222539A1
· Tabuteau
· 2020
[cited by applicant]
US 20200230239A1
· Tabuteau
· 2020
[cited by applicant]
US 20200230240A1
· Tabuteau
· 2020
[cited by applicant]
US 20200230241A1
· Tabuteau
· 2020
[cited by applicant]
US 20200246461A1
· Tabuteau
· 2020
[cited by applicant]
US 20200246462A1
· Tabuteau
· 2020
[cited by applicant]
US 20200254097A1
· Tabuteau
· 2020
[cited by applicant]
US 20200261466A1
· Tabuteau
· 2020
[cited by applicant]
US 20200261467A1
· Tabuteau
· 2020
[cited by applicant]
US 20200276311A1
· Tabuteau
· 2020
[cited by applicant]
US 20200289524A1
· Tabuteau
· 2020
[cited by applicant]
US 20200330476A1
· Tabuteau
· 2020
[cited by applicant]
US 20200338198A1
· Tabuteau
· 2020
[cited by applicant]
US 20200376124A1
· Tabuteau
· 2020
[cited by applicant]
US 20200376125A1
· Tabuteau
· 2020
[cited by applicant]
US 20200405861A1
· Tabuteau
· 2020
[cited by applicant]
US 20200405862A1
· Tabuteau
· 2020
[cited by applicant]
US 20210000956A1
· Tabuteau
· 2021
[cited by applicant]
US 20210008211A1
· Tabuteau
· 2021
[cited by applicant]
US 20210030876A1
· Tabuteau
· 2021
[cited by applicant]
US 20210121474A1
· Tabuteau
· 2021
[cited by applicant]
US 20210128575A1
· Tabuteau
· 2021
[cited by applicant]
US 20210128576A1
· Tabuteau
· 2021
[cited by applicant]
US 20210154299A1
· Tabuteau
· 2021
[cited by applicant]
US 20210177971A1
· Tabuteau
· 2021
[cited by applicant]
US 20210177972A1
· Tabuteau
· 2021
[cited by applicant]
US 20210196726A1
· Tabuteau
· 2021
[cited by applicant]
US 20210228592A1
· Tabuteau
· 2021
[cited by applicant]
US 20210260193A1
· Tabuteau
· 2021
[cited by applicant]
US 20210260194A1
· Tabuteau
· 2021
[cited by applicant]
US 20210275670A1
· Tabuteau
· 2021
[cited by applicant]
US 20210322552A1
· Tabuteau
· 2021
[cited by applicant]
US 20210346393A1
· Tabuteau
· 2021
[cited by applicant]
US 20210353636A1
· Tabuteau
· 2021
[cited by applicant]
US 20210361667A1
· Tabuteau
· 2021
[cited by applicant]
US 20210369729A1
· Tabuteau
· 2021
[cited by applicant]
US 20210369845A1
· Tabuteau
· 2021
[cited by applicant]
US 20210393782A1
· Tabuteau
· 2021
[cited by applicant]
US 20210401988A1
· Tabuteau
· 2021
[cited by applicant]
US 20220008539A1
· Tabuteau
· 2022
[cited by applicant]
US 20220054498A1
· Tabuteau
· 2022
[cited by applicant]
US 20220088027A1
· Tabuteau
· 2022
[cited by applicant]
US 20220096490A1
· Tabuteau
· 2022
[cited by applicant]
US 20220105104A1
· Tabuteau
· 2022
[cited by applicant]
US 20220175792A1
· Tabuteau
· 2022
[cited by applicant]
US 20220175927A1
· Tabuteau
· 2022
[cited by applicant]
US 20220211851A1
· Tabuteau
· 2022
[cited by applicant]
US 20220218718A1
· Tabuteau
· 2022
[cited by applicant]
US 20220233698A1
· Tabuteau
· 2022
[cited by applicant]
US 20220241292A1
· Tabuteau
· 2022
[cited by applicant]
US 20220313824A1
· Tabuteau
· 2022
[cited by applicant]
US 20220331428A1
· Tabuteau
· 2022
[cited by applicant]
US 20230000879A1
· Tabuteau
· 2023
[cited by applicant]
US 20230000880A1
· Tabuteau
· 2023
[cited by applicant]
US 20230016504A1
· Tabuteau
· 2023
[cited by applicant]
US 20230025944A1
· Tabuteau
· 2023
[cited by applicant]
US 20230042938A1
· Tabuteau
· 2023
[cited by applicant]
US 20230097899A1
· Tabuteau
· 2023
[cited by applicant]
US 20230108797A1
· Tabuteau
· 2023
[cited by applicant]
US 20230131057A1
· Tabuteau
· 2023
[cited by applicant]
US 20230173072A1
· Tabuteau
· 2023
[cited by applicant]
US 20230218762A1
· Tabuteau
· 2023
[cited by applicant]
US 20230233574A1
· Tabuteau
· 2023
[cited by applicant]
US 20230285306A1
· Tabuteau
· 2023
[cited by applicant]
US 20230338390A1
· Tabuteau
· 2023
[cited by applicant]
US 20230372355A1
· Tabuteau
· 2023
[cited by applicant]
US 20240058354A1
· Tabuteau
· 2024
[cited by applicant]
US 20240066036A1
· Tabuteau
· 2024
[cited by applicant]
US 20240082254A1
· Tabuteau
· 2024
[cited by applicant]
US 20240100060A1
· Tabuteau
· 2024
[cited by applicant]
US 20240261407A1
· Tabuteau
· 2024
[cited by applicant]
US 20240293342A1
· Tabuteau
· 2024
[cited by applicant]
US 20240307408A1
· Tabuteau
· 2024
[cited by applicant]
US 20250205246A1
· Tabuteau
· 2025
[cited by applicant]
US 20250255880A1
· Tabuteau
· 2025
[cited by applicant]
AU 2018205790B2
· 2018
[cited by applicant]
CA 2565941A1
· 2005
[cited by applicant]
CN 101984960A
· 2011
[cited by applicant]
CN 101987081
· 2011
[cited by applicant]
CN 102526058A
· 2012
[cited by applicant]
WO 1998006392A1
· 1998
[cited by applicant]
WO 1999009988A1
· 1999
[cited by applicant]
WO 2000035448
· 2000
[cited by applicant]
WO 2000059475
· 2000
[cited by applicant]
WO 2005021041A1
· 2005
[cited by applicant]
WO 2005076987
· 2005
[cited by applicant]
WO 2005105102A1
· 2005
[cited by applicant]
WO 2008006216
· 2008
[cited by applicant]
WO 2009152192A1
· 2009
[cited by applicant]
WO 2012072570
· 2012
[cited by applicant]
WO 2014161131A1
· 2014
[cited by applicant]
WO 2016131067
· 2016
[cited by applicant]
WO 2017042607
· 2017
[cited by applicant]
WO 2018129220A1
· 2018
[cited by applicant]
WO 2018209150A1
· 2018
[cited by applicant]
WO 2020010196A1
· 2020
[cited by applicant]
WO 2021207253A1
· 2021
[cited by applicant]
WO 2022147155A1
· 2022
[cited by applicant]
Mannix, “A Review of the 5-HT1B/1D Agonist Rizatriptan: Update on Recent Research and Implications for the Future”, Expert Opinion on Pharmacotherapy, 9(6): 1001-1011, Apr. 2008.
[cited by applicant]
Straube et al., “Combined Analgesics in (Headache) Pain Therapy: Shotgun Approach or Precise Multi-Target Therapeutics?”, BMC Neurology, 11:43, 2011.
[cited by applicant]
Axsome Therapeutics, Inc., “Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine”, Press Release, Nov. 28, 2017.
[cited by applicant]
Hu et al., Predicting Biological Functions of Compounds Based on Chemical-Chemical Interactions, PLoS One, 6(12), Dec. 2011, 9 pgs.
[cited by applicant]
Johnell et al., Concomitant Use of Gastroprotective Drugs Among Elderly NSAID/COX-2 Selective Inhibitor Users: A Nationwide Register-Based Study, Clinical Drug Investigation, 28(11), 687-695, Nov. 2008.
[cited by applicant]
Leonard et al., Proton Pump Inhibitors and Traditional Nonsteroidal Anti-Inflammatory Drugs and the Risk of Acute Interstitial Nephritis and Acute Kidney Injury, Pharmacoepidemiology and Drug Safety, 21(11), 1155-1172, …
[cited by applicant]
Vonkeman et al., Proton-Pump Inhibitors are Associated with a Reduced Risk for Bleeding and Perforated Gastroduodenal Ulcers Attributable to Non-Steroidal Anti-Inflammatory Drugs: A Nested Case-Control Study, Arthritis …
[cited by applicant]
Yilmaz et al., Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding?, Digestive Diseases and Sciences, 52(1), 110-11…
[cited by applicant]
International search report dated Aug. 11, 2016, corresponding to international patent application No. PCT/US2016/026991.
[cited by applicant]
Written opinion of the international searching authority dated Aug. 11, 2016, corresponding to international patent application No. PCT/US2016/026991.
[cited by applicant]
Stella et al., Toxicologic Pathology, 2008, 36:30-42.
[cited by applicant]
Jain et al., AAAPS PharmSciTech, 2011, 12(4):1163-1175.
[cited by applicant]
Baboota et al., Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2005, 51:219-224.
[cited by applicant]
Hosie et al., British Journal of Rheumatology, 35 (suppl. 1), 39-43, 1996.
[cited by applicant]
Wojtulewski et al., British Journal of Rheumatology; 35 (suppl. 1), 22-28,1996.
[cited by applicant]
Goldstein et al., Intragastric Acid Control in Non-Steroidal Anti-inflammatory Drug Users: Comparison of Esomeprazole, Lansoprazole and Pantoprazole, Alimentary Pharmacology & Therapeutics 23, 1189-1196, 2006.
[cited by applicant]
Euller-Ziegler et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration, Inflamm. res. 50, Supplement 1, S5-S9, 2001.
[cited by applicant]
Yoko Pharmaceuticals, Vivlodex Label, Oct. 2015.
[cited by applicant]
Mayo Clinic, http://web. archive.org/web/20141113013539/https:// www.mayoclinic.org/drugs-supplements /meloxicam-oral-route/proper-use/drg-20066928 (bearing an alleged date of 2014) (retrieved from the internet Mar. 3, …
[cited by applicant]
Láinez, “Rizatriptan in the treatment of migraine.” Neuropsychiatric disease and treatment, 2(3), p. 247, Sep. 2006.
[cited by applicant]
Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine. CNS drugs, 18(6), 337-42, May 2004.
[cited by applicant]
Weatherall, “Drug therapy in headache,” Clin. Med. (Lond.), 15(3), 273-279, Jun. 2015. (PMID: 26031979, Year 2015).
[cited by applicant]
Cameron C, et al., Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis, DOI: 10.1111/head.12601, https://www.nobi.nlm.nih.gov/pubmed/26178694, accessed on Mar. 25, 2020.
[cited by applicant]
Ng-Mak DS, et al., Acute migraine treatment with oral triptans and NSAIDs in a managed care population, DOI: 10.1111/j.1526-4610.2007.01055.x, https://www.ncbi.nlm.nih.gov/pubmed/18819177, accessed on Mar. 25, 2020.
[cited by applicant]
Lipton RB, et al., Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study, DOI: 10.1111/head.12201, https://www.ncbi.nim.nih.gov/pubmed/…
[cited by applicant]
Robert T., Migraine Management Essential 6: Rescue treatment; bearing an alleged date of Apr. 2011, https://migraine.com/blog/migraine-management-rescue-treatment/, accessed on Apr. 15, 2020.
[cited by applicant]
American Headache Society, Home/News /MAST Study Identifies Most Bothersome Symptom (MBS) for Patients with Migraine, https://americanheadachesociety.org/news/mast-most-bothersome-symptom/, accessed on May 7, 2020.
[cited by applicant]
Munjal et al., Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study, The Journal of Head and Face Pain, https://headachejournal.onlinelibrary.wiley.c…
[cited by applicant]
International Search Report and Written Opinion, PCT/US2019/040495, mailed Oct. 31, 2019.
[cited by applicant]
Deshpande et al., Bi-layer tablets—An emerging trend: a review, International journal of pharmaceutical sciences and research, 2(10): 2534-2544, Oct. 1, 2011.
[cited by applicant]
International Search Report, PCT/US2020/017046, mailed Jun. 4, 2020.
[cited by applicant]
Written Opinion of the International Searching Authority, PCT/US2020/017046, mailed Jun. 4, 2020.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2019/040495, mailed Jan. 14, 2021.
[cited by applicant]
Lionetto et al., Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs, 17(3): 393-406, Sep. 2012.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, PCT/US2021/026027, mailed Jun. 4, 2021.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, PCT/US2019/053167, mailed Jan. 9, 2020.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2020/017046, mailed Aug. 19, 2021.
[cited by applicant]
Pardutz et al., “NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data”, Pharmaceuticals, 3 (6), 1966-1987, Jun. 2010.
[cited by applicant]
Dalal et al., Meloxicam and Risk of Myocardial Infarction: A Population-based Nested Case-control Study, Rheumatol Int., 37(12), 2071-2078, Dec. 2017.
[cited by applicant]
Highlights of Prescribing Information for Mobic® (meloxicam) tablets, oral suspension (Initial U.S. Approval: 2000).
[cited by applicant]
Oregon State University, New Drug Review: Treximet® (Sumatriptan-Naproxen).
[cited by applicant]
Yuan et al., Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study, Headache: The Journal of Head and Face Pain, 61(9), 1432-1440, Oct. 2021.
[cited by applicant]
Edwards et al., Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function, Headache: The Journal of Head and Face Pain, 53(4…
[cited by applicant]
Khoury et al., Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal, Drug Design, Development and Therapy, 4, 9-17, 2010.
[cited by applicant]
Buse et al., Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study, The…
[cited by applicant]
Singh et al., Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam, Am J Med., 117(2), 100-106, Jul. 2004.
[cited by applicant]
Syed, Y.Y., Sumatriptan/Naproxen Sodium: A Review in Migraine, Drugs, 76(1), 111-121, Jan. 2016.
[cited by applicant]
Visser et al., Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group, Arch Neurol., 53(11),1132-1137, Nov. 1996.
[cited by applicant]
Highlights of Prescribing Information for VIVLODEX™, Medication Guide for VIVLODEX (meloxicam) capsules, for oral use (Initial U.S. Approval: 2000), issued or revised: Oct. 2015.
[cited by applicant]
Ekusheva et al., The actual approaches to therapy of refractory migraine. Medical Journal of the Russian Federation, 20(5):45-52, Oct. 2014. (with English Abstract).
[cited by applicant]
Pomeroy et al., Ketamine Infusions for Treatment Refractory Headache, Headache: The Journal of Head and Face Pain, 57(2), 276-282, Feb. 2017.
[cited by applicant]
Ferrari et al., Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials, The Lancet, 358, 1668-1675, Nov. 2001.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2021/026027, mailed Oct. 20, 2022.
[cited by applicant]
Furst et al., Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac, The Journal of rheumatology,…
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2021/065552, mailed Jul. 13, 2023.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2023/067172 mailed Jul. 28, 2023.
[cited by applicant]
Jones, A. et al. “Treatment of Migraine Pain and Associated Symptoms with AXS-07: Results from Movement, a Long-term Efficacy and Safety Study” American Headache Society Virtual Annual Scientific Meeting Jun. 3-6, 2021,…
[cited by applicant]
Thomas, Z. et al. “Identifying areas of unmet need among migraineurs with inadequate response to acute therapies: Results from the Momentum trial” Headache (May 20, 2022) vol. 62, Issue S1, Special Issue: American Heada…
[cited by applicant]
Jones, A. et al. “Efficacy of AXS-07 (MoSEICTM meloxicam and rizatriptan) in patients with risk factors for inadequate response to acute migraine medications” Headache (May 20, 2022) vol. 62, Issue S1, Special Issue: Am…
[cited by applicant]
Lipton et al., “Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine,” Neurology, 84(7), 688-695, Feb. 2015.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2024/044700 mailed Sep. 27, 2024.
[cited by applicant]
Tepper et al., “Efficacy of AXS-07 (Moseic™ Meloxicam and Rizatriptan) in Patients with Risk Factors for Inadequate Response to Acute Migraine Medications (P13-12.001).” Neurology, Apr. 25, 2023, vol. 100, No. 17, suppl…
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2023/067172, mailed Nov. 28, 2024.
[cited by applicant]
International Search Report and Written Opinion for PCT/US25/23660 mailed on Jun. 27, 2025.
[cited by applicant]
Meglio, M. “Emerge Study Aims to Highlight Therapeutic Benefit of AXS-07 After CGRPs Fail.” Neurology Live, vol. 6 No. 1, p. 18, 2023.
[cited by applicant]